Hormonal
GLP-1 receptor agonists (GLP-1RA) and related incretin mimetics (e.g., semaglutide, tirzepatide, retatrutide) produce significant weight loss in adults with obesity, achieving reductions comparable to bariatric surgery.
GLP-1 medications like Semaglutide and Tirzepatide are highly effective for weight loss, often achieving 15-24% body weight reduction, which rivals bariatric surgery. They work by increasing satiety and slowing digestion. Because obesity is chronic, these drugs likely need to be taken long-term to maintain weight loss. Side effects are mostly gastrointestinal (nausea), but serious risks exist for those with specific thyroid cancer histories. Consult a doctor to see if you are a candidate.
GLP-1-RA und andere Inkretinmimetika können das Sättigungsgefühl erhöhen und den Appetit verringern... Die Erfolge einer medikamentösen Therapie vor der GLP1-RA-Ära waren eher bescheiden... Die Maximaltherapie der Adipositas besteht in der bariatrischen bzw. metabolischen Chirurgie... Die Erfolge einer medikamentösen Therapie vor der GLP1-RA-Ära waren eher bescheiden... Die Maximaltherapie der Adipositas besteht in der bariatrischen bzw. metabolischen Chirurgie. Durch einen Magenbypass beispielsweise ist eine Gewichtsreduktion von bis zu 30 % des Körpergewichts im Durchschnitt möglich.
Why this rating
Based on multiple Phase II and III clinical trials cited (STEP series, SURPASS, etc.), though it is a review article summarizing these studies rather than a primary trial itself.
Source
„Glucagon-like peptide‑1“(GLP‑1)-Rezeptor-Agonisten – die neuen Wunderwaffen in der Adipositastherapie?
Dirk Raddatz · Journal für Gastroenterologische und Hepatologische Erkrankungen · 2023
DOI 10.1007/s41971-023-00170-3
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →